The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression

Experimental Cell Research

Volumn 318, Issue 13, 2012, Pages 1554-1563

  Miyake, Kotaro ^a   Nishioka, Masanori ^a   Imura, Satoru ^a   Batmunkh, Erdenebulgan ^a   Uto, Yoshihiro ^a   Nagasawa, Hideko ^b   Hori, Hitoshi ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bioreductive agent; Hypoxia inducible factor 1; Hypoxic cytotoxin; Pancreatic cancer; TX 2098

Indexed keywords

3 [2 HYDROXYETHYL(METHYL)AMINO] 2 QUINOXALINECARBONITRILE 1,4 DIOXIDE; ANTINEOPLASTIC AGENT; CYTOTOXIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TX 2098; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 84862027970     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.03.013     Document Type: Article

References (53)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA Cancer J. Clin. 1997, 47:5-27.
2. Howard T.J. Pancreatic adenocarcinoma. Curr. Probl. Cancer 1996, 20:281-328.
3. Yeo T.P., Hruban R.H., Leach S.D., Wilentz R.E., Sohn T.A., Kern S.E., Iacobuzio-Donahue C.A., Maitra A., Goggins M., Canto M.I., Abrams R.A., Laheru D., Jaffee E.M., Hidalgo M., Yeo C.J. Pancreatic cancer. Curr. Probl. Cancer 2002, 26:176-275.
4. Miyake K., Imura S., Yoshizumi T., Ikemoto T., Morine Y., Shimada M. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int. J. Clin. Oncol. 2007, 12:111-119.
5. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
6. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
7. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56:941-943.
8. Stadler P., Becker A., Feldmann H.J., Hansgen G., Dunst J., Wurschmidt F., Molls M. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44:749-754.
9. Karademir S., Sokmen S., Terzi C., Sagol O., Ozer E., Astarcioglu H., Coker A., Astarcioglu I. Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J. Hepatobiliary Pancreat. Surg. 2000, 7:489-495.
10. Khan A.W., Dhillon A.P., Hutchins R., Abraham A., Shah S.R., Snooks S., Davidson B.R. Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur. J. Surg. Oncol. 2002, 28:637-644.
11. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239-2245.
12. Kitada T., Seki S., Sakaguchi H., Sawada T., Hirakawa K., Wakasa K. Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology 2003, 43:550-555.
13. Hansel D.E., Rahman A., Hermans J., de Krijger R.R., Ashfaq R., Yeo C.J., Cameron J.L., Maitra A. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod. Pathol. 2003, 16:652-659.
14. Sipos B., Weber D., Ungefroren H., Kalthoff H., Zuhlsdorff A., Luther C., Torok V., Kloppel G. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study. Int. J. Cancer 2002, 102:592-600.
15. Brown J.M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 2000, 6:157-162.
16. Rofstad E.K. Microenvironment-induced cancer metastasis. Int. J. Radiat. Biol. 2000, 76:589-605.
17. Brown J.M., Wang L.H. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des. 1998, 13:529-539.
18. Junnotul V., Sarkar U., Sinha S., Gates K.S. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide. J. Am. Chem. Soc. 2009, 28:1015-1024.
19. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P., Talbot D., Rey A., Butler T.W., Hirsh V., Olver I., Bergman B., Ayoub J., Richardson G., Dunlop D., Arcenas A., Vescio R., Viallet J., Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated nonsmall-cell lung tumors. J. Clin. Oncol. 2000, 18:1351-1359.
20. Rischin D., Peters L., Fisher R., Macann A., Denham J., Poulsen M., Jackson M., Kenny L., Penniment M., Corry J., Lamb D., McClure B. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 2005, (23):79-87.
21. Rischin D., Peters L.J., O'Sullivan B., Giralt J., Fisher R., Yuen K., Trotti A., Bernier J., Bourhis J., Ringash J., Henk M., Kenny L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 2009, (27):4449.
22. Nagasawa H., Yamashita M., Mikamo N., Shimamura M., Oka S., Uto Y., Hori H. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2002, 132:33-40.
23. Diab-Assef M., Haddadin M.J., Yared P., Assaad C., Gali-Muhtasib H.U. Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents. Mol. Carcinog. 2002, 33:198-205.
24. Shimamura M., Nagasawa H., Ashino H., Yamamoto Y., Hazato T., Uto Y., Hori H., Inayama S. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors. Br. J. Cancer 2003, 88:307-313.
25. Hay M.P., Gamage S.A., Kovacs M.S., Pruijn F.B., Anderson R.F., Patterson A.V., Wilson W.R., Brown J.M., Denny W.A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 2003, 46:169-182.
26. Miyake K., Shimada M., Nishioka M., Sugimoto K., Batmunkh E., Uto Y., Nagasawa H., Hori H. Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. Cancer Chemother. Pharmacol. 2009, 64:885-892.
27. Miyake K., Imura S., Nishioka M., Batmunkh E., Sugimoto K., Ohmoto Y., Shimada M. Serum evaluation of soluble interferon-alpha/beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine 2010, 49:251-255.
28. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
29. Miyake K., Tsuchida K., Sugino H., Imura S., Morine Y., Fujii M., Shimada M. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother. Pharmacol. 2007, 59:113-126.
30. Nagasawa H., Mikamo N., Nakajima Y., Matsumoto H., Uto Y., Hori H. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. Anticancer Res. 2003, 23:4427-4434.
31. Miyake K., Yoshizumi T., Imura S., Sugimoto K., Batmunkh E., Kanemura H., Morine Y., Shimada M. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36:e1-e9.
32. Hockel M., Schlenger K., Knoop C., Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 1991, 51:6098-6102.
33. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38:285-289.
34. Brizel D.M., Dodge R.K., Clough R.W., Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 1999, 53:113-117.
35. Cairns R., Papandreou I., Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 2006, 4:61-70.
36. Ranniger K., Saldino R.M. Arteriographic diagnosis of pancreatic lesions. Radiology 1966, 86:470-474.
37. Yassa N.A., Yang J., Stein S., Johnson M., Ralls P. Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma. J. Clin. Ultrasound 1997, 25:473-480.
38. Megibow A.J. Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions. Radiology 1992, 183:297-303.
39. Koong A.C., Mehta V.K., Le Q.T., Fisher G.A., Terris D.J., Brown J.M., Bastidas A.J., Vierra M. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:919-922.
40. Brahimi-Horn C., Berra E., Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol. 2001, 11:S32-S36.
41. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269:23757-23763.
42. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
43. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:17771-17778.
44. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001, 61:6669-6673.
45. Hartmann A., Kunz M., Kostlin S., Gillitzer R., Toksoy A., Brocker E.B., Klein C.E. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res. 1999, 59:1578-1583.
46. Koga J., Kakeji Y., Sumiyoshi Y., Kimura Y., Shibahara K., Emi Y., Maehara Y., Sugimachi K. Angiogenesis and macrophage infiltration in Borrmann type IV gastric cancer. Fukuoka Igaku Zasshi 2001, 92:334-339.
47. Borgstrom P., Hillan K.J., Sriramarao P., Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996, 56:4032-4039.
48. Brekken R.A., Thorpe P.E. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 2001, 21:4221-4229.
49. Patterson A.V., Williams K.J., Cowen R.L., Jaffar M., Telfer B.A., Saunders M., Airley R., Honess D., van der Kogel A.J., Wolf C.R., Stratford I.J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 2002, 9:946-954.
50. Shibata T., Giaccia A.J., Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 2002, 4:40-48.
51. Rosenberg A., Knox S. Radiation sensitization with redox modulators: a promising approach. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64:343-354.
52. Covens A., Blessing J., Bender D., Mannel R., Morgan M. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 2006, 100:586-590.
53. Masunaga S., Nagasawa H., Uto Y., Hori H., Onishi K., Takahashi A., Ohnishi T., Suzuki M., Nagata K., Kinashi Y., Ono K. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells. Oncol. Rep. 2005, 14:393-400.